| 구분 | 보고서 (영문) |
| 제약/바이오/임 상시험 |
Takeda’s Eohilia to Compete Sanofi’s Dupixent in Eosinophilic Esophagitis Treatment |
| eConsent: The Overlooked Patient-Centric Tool | |
| The Magrolimab Trial Halt Highlights the Uncertainties in Anti-CD47 Immunotherapy | |
| The Tiny Pills That May Send Shockwaves Across Immunology | |
| Cell and Gene Therapy Landscape in the US | |
| Another Setback for Minerva’s Schizophrenia Treatment Roluperidone | |
| APAC Led in Trials for 2023, with the Majority in Phase II | |
| Oncology Emerges as Dominant Therapy Area for CRISPR Technology |
|
| Allecra’s EXBLIFEP Provides Valuable New Weapon to Tackle ESBL Mediated AMR | |
| AbbVie and Genmab’s Epkinly Joins BiTE Competition in Follicular Lymphoma |
|
| 질환별 | Comorbidities Associated with ADHD Present an Opportunity for Pipeline Products to Capture the Market |
| Female Sexual Dysfunction: Competitive Landscape | |
| Shifting the Paradigm – Novel Approaches to Amyotrophic Lateral Sclerosis Therapy | |
| Cell & Gene Therapies in Hemophilia A & B | |
| Shifting Patterns in Cervical Cancer Cases in Women in Their 30s and 40s | |
| 컨퍼런스/심포 지엄/학회/기타 |
IO360: First Allogeneic Dual CAR T-Cell Therapy Shows Promise in B Cell Non-Hodgkin Lymphom |
| Biotech Funding Optimism Rises as 44% Predict Recovery in 2024 | |
| Market Cap Upturn for Top 20 Biopharma Companies with Obesity Drug Successes in 2023 | |
| AD/PD 2024: The Role of Blood-Based Biomarkers in Alzheimer’s Disease |
|
| AD/PD 2024: Promising Data for Monitoring Speech Deficits in Early Parkinson’s |
'의료기기관련기관 > 국가임상시험지원재단' 카테고리의 다른 글
| [KoNECT] 해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 (0) | 2024.03.15 |
|---|---|
| [KoNECT] 해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 (0) | 2024.03.15 |
| [KoNECT] 해외 임상시험 정보 데이터(GlobalData) 보고서 (0) | 2024.03.15 |
| [KoNECT] 해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 안내 1.22.(월) (0) | 2024.01.24 |
| [KoNECT] 해외 임상시험 정보 데이터(Global Data) 보고서 업데이트 (0) | 2024.01.08 |